Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2021 ) > List of Articles

REVIEW ARTICLE

Practical Approach for the Diagnosis, Prevention, and Management of Recurrent Upper Respiratory Tract Infection in Children: Report from an Expert Closed-group Discussion

Kuravi Nagaraju, Raju Shah, Sridhar Ganapathy, Sitesh Roy, Rakesh Bhatia, Paramjeet S Kumar, Sanjiv Kanaujia, Archana Karadkhele, Snehal Muchhala, Rahul Rathod, Viraj Suvarna

Keywords : Children, Cough, Levosalbutamol, Pediatrics, Respiratory tract infections

Citation Information : Nagaraju K, Shah R, Ganapathy S, Roy S, Bhatia R, Kumar PS, Kanaujia S, Karadkhele A, Muchhala S, Rathod R, Suvarna V. Practical Approach for the Diagnosis, Prevention, and Management of Recurrent Upper Respiratory Tract Infection in Children: Report from an Expert Closed-group Discussion. Pediatr Inf Dis 2021; 3 (3):105-112.

DOI: 10.5005/jp-journals-10081-1321

License: CC BY-NC 4.0

Published Online: 16-09-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Respiratory tract infections (RTIs) are one of the most common infections in childhood. Due to the weaning of maternal immunity during the first year of life and relative immaturity of the immune system, children in the age group of 6 months to 6 years are predisposed to RTIs. Several guidelines are available from western countries on the diagnosis and management of RRTIs. However, owing to the economic, nutritional, environmental, geographic, and social diversity of India, the practical approach to RRTIs, especially, the recurrent URTIs, is likely to differ warranting the need for local guidelines. This expert consensus offers a practical guide for the diagnosis, prevention, and management of recurrent URTIs in pediatric outpatient settings in India.


PDF Share
  1. Toivonen L, Karppinen S, Schuez-Havupalo L, et al. Burden of recurrent respiratory tract infections in children: a prospective cohort study. Pediatr Infect Dis J 2016;35(12):e362–e369. DOI: 10.1097/INF.0000000000001304.
  2. Paramesh H, Nagaraju K, Sukumarn TU, et al. Recurrent respiratory infections management in India: consensus statement from experts. Asian J Paediat Pract 2017;1(3):7–15. DOI: 10.5772/19422.
  3. Bellanti A. Recurrent respiratory tract infections in paediatric patients. Drugs 1997;54(Supplement 1):1–4. DOI: 10.2165/00003495-199700541-00003.
  4. Rovers MM, Balemans WA, Sanders EA, et al. Persistence of upper respiratory tract infections in a cohort followed from childhood to adulthood. Fam Pract 2006;23(3):286–290. DOI: 10.1093/fampra/cml001.
  5. Parmar SM, Sood A, Chakkal HS. Prevalence of chronic suppurative otitis media in schoolgoing children. Indian J Otol 2018;24:223–236. DOI: 10.4103/indianjotol.INDIANJOTOL_152_17.
  6. Schaad UB, Esposito S, Razi CH. Diagnosis and management of recurrent respiratory tract infections in children: a practical guide. Arch Pediatr Infect Dis 2016;4(1):e31039. DOI: 10.5812/pedinfect.31039.
  7. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014;5:446. DOI: 10.3389/fimmu.2014.00446.
  8. Lehtoranta L, Latvala S, Lehtinen MJ. Role of probiotics in stimulating the immune system in viral respiratory tract infections: a narrative review. Nutrients 2020;12(10):3163. DOI: 10.3390/nu12103163.
  9. Jesenak M, Ciljakova M, Rennerova Z, et al., Recurrent respiratory infections in children – Definition, diagnostic approach, treatment and prevention. Available from: https://www.intechopen.com/books/bronchitis/recurrent-respiratory-infections-in-children-definition-diagnostic-approach-treatment-and-prevention Accessed on: 18 December 2020 3). DOI: 10.5772/19422.
  10. de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol 2007;18(s18):13–18. DOI: 10.1111/j.1399-3038.2007.00625.x.
  11. Suguna E, Kumar SG, Roy G. Prevalence and risk factors of acute respiratory infection among school children in coastal South India. J Glob Infect Dis 2014;6(3):95–98. DOI: 10.4103/0974-777X.138498.
  12. van Niekerk A, Esser N. A diagnostic approach to recurrent respiratory tract infections in childhood: could it be primary immunodeficiency? Curr Aller Clin Immunol 2015;28:308–312.
  13. de Vries E. Immunological investigations in children with recurrent respiratory infections. Paediatr Respir Rev 2001;2(1):32–36. DOI: 10.1053/prrv.2000.0099.
  14. Approved drugs by CDSCO. Available from: https://cdscoonline.gov.in/CDSCO/Drugs. Accessed on: 18 December 2020.
  15. Paramesh H, Nimain M, Vijay K, et al. Cough profile and trends in cough management in children across India: results of a multi-centric, cross-sectional survey. New Indian J Pediat 2019;8:1–24.
  16. Vora A, Krishnaprasad K. Bhargava A for BUS panel. A cross-sectional cohort analyses assessing response to levosalbutamol bronchodilatory cough formulations in outpatient community settings of India: ‘BUS’ analyses. JAPI 2016;64(9):45–48.
  17. Kiran MD, Pawaskar LJ, Sheikh SN. Efficacy and safety for the combination of levosalbutamol, ambroxol, and guaifenesin for the symptomatic treatment of productive cough. Phase IV clinical trial. IJIRMS 2019;4(5):11–15. DOI: 10.23958/ijirms/vol04-i01/537.
  18. Kiran MD, Sheikh SN, Pawaskar LJ. Efficacy and safety for the combination of terbutaline, ambroxol, and guaifenesin for the symptomatic treatment of productive cough. Phase IV clinical trial. IJIRMS 2019;5(5):4005–4008. DOI: 10.23958/ijirms/vol04-i01/537.
  19. Cotton M, Innes S, Jaspan H, et al. Management of upper respiratory tract infections in children. S Afr Fam Pract (2004) 2008;50(2):6–12. DOI: 10.1080/20786204.2008.10873685.
  20. Hersh AL, Jackson MA, Hicks LA. American Academy of Pediatrics Committee on Infectious Diseases. Principles of judicious antibiotic prescribing for upper respiratory tract infections in pediatrics. Pediatrics 2013;132(6):1146–1454. DOI: 10.1542/peds.2013-3260.
  21. Pani A, Lauriola M, Romandini A, et al. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology [published online ahead of print, 2020 Jun 10]. Int J Antimicrob Agents 2020(2):106053. DOI: 10.1016/j.ijantimicag.2020.106053.
  22. Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012;2012:649570. DOI: 10.1155/2012/649570.
  23. Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotics, inhibits influenza A(H1N1) pdm09 virus infection by interfering with virus internalization process. J Antibiot(Tokyo) 2019;72(10):759–768. DOI: 10.1038/s41429-019-0204-x.
  24. Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2018;392(10154):1197–1206. DOI: 10.1016/S0140-6736(18)31723-9.
  25. Donde S, Mishra A, Kochhar P. Azithromycin in acute bacterial upper respiratory tract infections: an Indian non-interventional study. Indian J Otolaryngol Head Neck Surg 2014;66(Suppl 1):225–230. DOI: 10.1007/s12070-011-0437-x.
  26. CDC. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis 2005 CDC guidelines. MMWR 2005;54:L1–L20.
  27. Bianchini S, Argentiero A, Camilloni B, et al. Vaccination against paediatric respiratory pathogens. Vaccines (Basel) 2019;7(4):168. DOI: 10.3390/vaccines7040168.
  28. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013;1(5):CD000980. DOI: 10.1002/14651858.CD000980.pub4.
  29. Calder C, Carr AC, Gombart AF. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 2020(4):12. DOI: 10.3390/nu12041181.
  30. Zhang X, Ding F, Li H, et al. Low serum levels of Vitamins A, D, and E are associated with recurrent respiratory tract infections in children living in Northern China: a case control study. PLoS ONE 2016;11(12):e0167689. DOI: 10.1371/journal.pone.0167689.
  31. Puggioni F, Alves-Correia M, Mohamed MF, et al. Immunostimulants in respiratory diseases: focus on pidotimod. Multidiscip Respir Med 2019;14(1):31. DOI: 10.1186/s40248-019-0195-2.
  32. Walavalkar KCP, Joshi M, Kelkar M, et al. Efficacy and safety of pidotimod as adjuvant in the treatment of recurrent upper respiratory tract infections (URTI) in children. Trends Med 2014;14:11–16.
  33. Niu H, Wang R, Jia YT, et al. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol 2019;67:35–45. DOI: 10.1016/j.intimp.2018.11.043.
  34. Esposito S, Soto-Martinez ME, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol 2018;18(3):198–209. DOI: 10.1097/ACI.0000000000000433.
  35. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, et al. Cochrane rReview: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Rev J 2012;7(5):629–717. DOI: 10.1002/ebch.1833.
  36. Ahanchian H, Jafari SA. Probiotics and prebiotics for prevention of viral respiratory tract infections. Probiot, Prebiot, Synbiot 2016. 575–583. DOI: 10.1016/B978-0-12-802189-7.00042-3.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.